Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Jun 26 23:00:50 UTC 2021
by
admin
on
Sat Jun 26 23:00:50 UTC 2021
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
GJD9I3123C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
GJD9I3123C
Created by
admin on Sat Jun 26 23:00:50 UTC 2021 , Edited by admin on Sat Jun 26 23:00:50 UTC 2021
|
PRIMARY | |||
|
P21730
Created by
admin on Sat Jun 26 23:00:50 UTC 2021 , Edited by admin on Sat Jun 26 23:00:50 UTC 2021
|
PRIMARY | |||
|
P21730
Created by
admin on Sat Jun 26 23:00:50 UTC 2021 , Edited by admin on Sat Jun 26 23:00:50 UTC 2021
|
PRIMARY |
| From | To |
|---|---|
| 1_109 | 1_188 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_5 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
INVERSE AGONIST->TARGET | |||
|
INHIBITOR -> TARGET |
IPH5401 is a therapeutic human antibody that specifically binds and blocks C5a receptors (C5aR) expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils. IPH5401 blocks the binding of C5a to C5aR, thereby reducing the accumulation and activation of MDSC and neutrophils in tumors. Treatment with IPH5401 may unleash anti-tumor activities of T cells and NK cells.
|
||
|
INHIBITOR -> TARGET |
ANTAGONIST
IC50
|
||
|
|
INHIBITOR -> TARGET |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|